Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Chronic Plaque Psoriasis Market?

In recent years, there has been a robust growth in the chronic plaque psoriasis market. The market, valued at $20.79 billion in 2024, is projected to expand to $22.32 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%. The notable growth during the historical period is attributable to factors such as an increasing number of psoriasis cases, rising incidences of related conditions, positive reimbursement policies, escalating consumption of alcohol and smoking, and the emergence of telemedicine.

What Growth Rate Is Forecasted for the Chronic Plaque Psoriasis Market by 2029?

The size of the chronic plaque psoriasis market is predicted to experience significant expansion in the forthcoming years, reaching $29.33 billion by 2029 with a 7.1% compound annual growth rate (CAGR). The anticipated growth during the forecast period is primarily due to rising or falling occurrence rates of cpp globally, an upsurge in autoimmune diseases, expanded healthcare budgets, an aging demography, and escalating demands for efficacious treatments. Prevailing trends that will shape the forecast period comprise breakthroughs in biologic treatments, the emergence of oral small molecule inhibitors, integration of digital health technologies, personalizing medication, and the advent of biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Key Companies Are Shaping the Future of the Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

Which Factors Are Driving Demand in the Chronic Plaque Psoriasis Industry?

The rise in instances of dysfunction in the immune system is anticipated to stimulate the expansion of the chronic plaque psoriasis market. This dysfunction, wherein the immune system’s proper functioning is compromised, thereby making individuals more vulnerable to infections, autoimmune diseases, and cancer, can be attributed to elements such as genetic predispositions, environmental triggers, and a lack of proper nutrition, chronic stress, and a surge in prevalence of autoimmune diseases and infections such as HIV. The treatment of chronic plaque psoriasis is critical to managing this immune system dysfunction, as an erring immune system could lead to overproduction of skin cells resulting in inflammation and plaque formation. For instance, the National Psoriasis Foundation, a not-for-profit organization based in the US, stated in December 2022 that psoriasis affects over 8 million Americans. Around the world, the condition affects 125 million individuals, accounting for 2 to 3% of the global population. As a result, the escalating number of instances of immune system dysfunction is fueling the surge in demand in the chronic plaque psoriasis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

How Is the Chronic Plaque Psoriasis Market Segmented by Several Divisions?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

What are the Emerging Market Trends Driving the Growth of the Chronic Plaque Psoriasis Industry?

Leading corporations in the chronic plaque psoriasis industry are centering their efforts on the creation of innovative solutions such as IL-17A and IL-17F inhibitors in a bid to progress treatment options in this field. These inhibitors function as targeted biologic treatments that inhibit interleukin-17A and interleukin-17F, cytokines responsible for inflaming autoimmune diseases like chronic plaque psoriasis. To illustrate, UCB S.A., a biopharmaceutical firm from Belgium, revealed in October 2023 that their drug BIMZELX (bimekizumab-bkzx) received approval from the U.S. Food and Drug Administration (FDA) for usage in adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. As the first medication developed specifically to target and block interleukin 17A (IL-17A) and interleukin 17F (IL-17F), Bimekizumab is a breakthrough in managing psoriasis. This FDA approval is backed by evidence gathered from three multicenter Phase 3 studies—BE READY, BE VIVID, and BE SURE—which collectively evaluated its safety and efficacy in 1,480 patients suffering from moderate to severe plaque psoriasis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Regions Are Driving Growth in the Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

This Report Delivers Insight On:

1. How big is the chronic plaque psoriasis market, and how is it changing globally?

2. Who are the major companies in the chronic plaque psoriasis market, and how are they performing?

3. What are the key opportunities and risks in the chronic plaque psoriasis market right now?

4. Which products or customer segments are growing the most in the chronic plaque psoriasis market?

5. What factors are helping or slowing down the growth of the chronic plaque psoriasis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model